Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interviews as Topic × Endocrine × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Breast 35 Gastrointestinal 34 Genitourinary 29 Tumor-Agnostic 23 Other hematologic neoplasm 23 Gynecologic 20 Other solid neoplasm 19 Thoracic 18 Lymphoid 14 Head & Neck 14 Other 7 Sarcoma 6 Plasma cell 6 CNS 6 Other neoplasm 4 Myeloid 4 Dermatologic 4 Endocrine 1 Classical hematology 1

Conditions

Non-resectable Metastatic Cancer of the Lung 1

Interventions

Everolimus 55 lutetium Lu 177 dotatate 48 Magnetic Resonance Spectroscopy 32 Cisplatin 25 pembrolizumab 24 Temozolomide 22 gallium Ga 68 dotatate 21 Octreotide 21 lanreotide 20 Nivolumab 20 Specimen Handling 17 3-Iodobenzylguanidine 17 cabozantinib 16 Etoposide 16 Sunitinib 15 Capecitabine 14 surufatinib 13 pasireotide 13 lenvatinib 13 dabrafenib 13 Paclitaxel 13 Carboplatin 13 trametinib 12 Surgical Procedures, Operative 11 Doxorubicin 11 Bevacizumab 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 Sorafenib 10 Ipilimumab 10 Injections 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03328065 2022-04-21

EOLE

Centre Hospitalier Universitaire Dijon

EndocrineGastrointestinal

Non-resectable Metastatic Cancer of the Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡